# US 2014/0234854 A1 · Method for evaluation of presence of or risk of colon tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0234854 A1
- Document ID: US20140234854A1
- Status: Published application
- Kind: A1
- Application number: 14/094,594
- Filed: 2013-12-02
- Published: 2014-08-21
- Earliest claimed: 2012-11-30
- Assignees: Applied Proteomics, Inc.
- Applicants: Applied Proteomics, Inc.
- Inventors: John Blume; Ryan Benz; Lisa Croner; Roslyn Dillon; Arlo Z. Randall; Jeffrey Jones; Heather Skor; Tom Stockfisch; Bruce Wilcox; Daniel Ruderman
- Web page: https://patentgrep.com/patent/US20140234854A1

## CPC

- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 40/20: Supervised data analysis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N 2800/7028: Cancer
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The disclosed methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management. The methodology provided herein is intended to detect technical variations and to allow for data normalization and enhance signal detection and build predictive proteins profiles of disease status and response.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method of detecting the presence or absence of an adenoma or polyp of the colon in a subject with a sensitivity of greater than 70% or a selectivity of greater than 70%:
(a) obtaining a biological sample from said subject;
(b) performing an analysis of the biological sample for the presence and amount of one or more peptides;
(c) comparing the presence and amount of one or more peptides from said biological sample to a control reference value to determine a positive or negative score for the presence of an adenoma or polyp of the colon with a sensitivity of greater than 70% or a selectivity of greater than 70%.

### Claim 12 (depends on 11)

The method of claim 11, wherein said method achieves a sensitivity or selectivity greater than 80%, greater than 85%, greater than 90%, greater than 95%, and greater than 99%.

### Claim at position 4

13-14. (canceled)

### Claim 15 (depends on 11)

The method of claim 11, further comprising preparing a report for said subject, wherein said report indicates the presence or absence of an adenoma or polyp.

### Claim 16

(canceled)

### Claim 17 (depends on 11)

The method of claim 11, wherein said method detects the presence or absence of an adenoma.

### Claim 18 (depends on 17)

The method of claim 17, wherein said adenoma is an adenomatous polyp or polypoid adenoma.

### Claim 19 (depends on 18)

The method of claim 18, wherein said adenomatous polyp or polypoid adenoma is selected from the group of pedunculated polyps and sessile polyps.

### Claim 20 (depends on 18)

The method of claim 18, wherein said adenomatous polyp or polypoid adenoma is characterized according to a degree of cell dysplasia or pre-malignancy.

### Claim 21 (depends on 11)

The method of claim 11, wherein said method further detects the presence or absence of colorectal carcinoma.

### Claim at position 12

22-23. (canceled)

### Claim 24 (depends on 11)

The method of claim 11, further comprising confirming said presence or absence of the adenoma or polyp of the colon by means selected from the group consisting of colonoscopy, imaging, and surgery.

### Claim 25 (depends on 11)

The method of claim 11, wherein said biological sample is selected from the group consisting of whole blood, serum, plasma, blood constituent, bone marrow, saliva, cheek swab, urine, stool, lymph fluid, CNS fluid, and lesion exudate.

### Claim 26 (depends on 25)

The method of claim 25, wherein said biological sample is selected from the group consisting of whole blood, serum, and plasma.

### Claim 27 (depends on 11)

The method of claim 11, wherein said subject is asymptomatic.

### Claim 28 (depends on 11)

The method of claim 11, wherein said subject is from 18 to 49 years old.

### Claim 29 (depends on 11)

The method of claim 11, wherein said subject has not previously received a colonoscopy.

### Claim 30 (depends on 11)

The method of claim 11, wherein said subject has no symptoms for colorectal carcinoma, no family history for colorectal carcinoma, and no recognized risk factors for colorectal carcinoma.

### Claim 31

(canceled)

### Claim 32 (depends on 11)

The method of claim 11, wherein said analysis of step (b) comprises performing one or more of a spectroscopic analysis, mass spectrometry, immunological analysis, and enzymatic reactivity analysis of said one or more peptides.

### Claim 33 (depends on 32)

The method of claim 32, wherein said analysis comprises performing a mass spectrometry analysis of said one or more peptides.

### Claim 34 (depends on 32)

The method of claim 32, wherein said immunological analysis comprises one or more of an enzyme-linked immunosorbent assay, radioimmunoassay, immunoblotting, immunodiffusion, immunoelectrophoresis, flow cytometry, and immunoprecipitation.

### Claim at position 24

35-36. (canceled)

### Claim 37 (depends on 11)

The method of claim 11, wherein said control reference is the presence and amount of a set of one or more non-overlapping proteins and/or peptides in the same biological sample.

### Claim 38 (depends on 11)

The method of claim 11, wherein said control reference is the presence and amount of an overlapping set of proteins and/or peptides obtained from one or more subjects in which adenoma or polyp of the colon is present.

### Claim 39 (depends on 11)

The method of claim 11, wherein said control reference is the presence and amount of an overlapping set of proteins and/or peptides obtained from one or more subjects in which adenoma or polyp of the colon is not present.

### Claim 40 (depends on 11)

The method of claim 11, wherein said analysis detects the presence and amount of a number of proteins or polypeptides, wherein said number is selected from at least 2, at least 5, at least 10, at least 50, at least 100, and at least 1000.

### Claim 41 (depends on 11)

The method of claim 11, wherein said one or more peptides comprises one or more of:
i) one or more proteins selected from the group consisting of SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, and the proteins in FIG. 9;
ii) one or more peptide fragments of SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, or the proteins in FIG. 9;
iii) one or more peptides with a sequence homology to SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, or the proteins in FIG. 9, wherein said sequence homology is selected from the group of greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, and greater than 99%; and
iv) one or more binding partners of SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, or the proteins in FIG. 9.

### Claim at position 30

42-47. (canceled)

### Claim 48 (depends on 11)

The method of claim 11, further comprising
(e) performing an analysis of the biological sample for the presence and amount of one or more analytes selected from the groups consisting of metabolites, DNA sequences, RNA sequences, and combinations thereof; and
(f) comparing the presence and amount of said analytes to a control reference value; and
(g) correlating the presence and amount of said analytes with the subject's adenoma or polyp status.

### Claim 49 (depends on 11)

The method of claim 11, wherein the subject has previously undergone a colonoscopy which yielded a negative result.

### Claim at position 33

50-85. (canceled)

### Claim 86 (depends on 11)

The method of claim 11, wherein the subject has been previously treated for adenoma or polyps of the colon.

### Claim at position 35

87-129. (canceled)

### Claim 130 (depends on 11)

A kit, comprising:
(a) a container for collecting a sample from a subject;
(b) means for detecting one or more proteins or peptides, or means for transferring said container to a test facility; and
(c) written instructions for performing the method of claim 11.

### Claim 131 (depends on 130)

The kit of claim 130, wherein said means for detecting one or more proteins or peptides comprises one or more antibodies that bind one or more of the following sets:
i) one or more proteins selected from the group consisting of SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, and the proteins in FIG. 9;
ii) one or more peptide fragments of SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), and ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, and/or the proteins in FIG. 9;
iii) one or more peptides with a sequence homology to SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, or the proteins in FIG. 9, wherein said sequence homology is selected from the group of greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, and greater than 99%;
iv) one or more binding partners of SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, or the proteins in FIG. 9; and
v) a protein or peptide from which one or more neutral mass clusters from FIG. 7 or FIG. 8 is derived.

### Claim 132 (depends on 131)

The kit of claim 131, wherein one or more antibodies are each tagged with a label.

### Claim 133 (depends on 132)

The kit of claim 132, wherein the label is selected from the group consisting of a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, and combinations thereof.

### Claim 134 (depends on 131)

The kit of claim 131, wherein the antibodies are packaged in an aqueous medium or in lyophilized form.

### Claim 135 (depends on 130)

The kit of claim 130, wherein said means for detecting one or more proteins or peptides comprises an enzyme-linked immunosorbent assay.

### Claim 136 (depends on 11)

The method of claim 11, wherein the one or more peptides is selected from the group consisting of ACTB, ACTH, ANGT, SAHH, ALDR, AKT1, ALBU, AL1A1, AL1B1, ALDOA, AMY2B, ANXA1, ANXA3, ANXA4, ANXA5, APC, APOA1, APOC1, APOH, GDIR1, ATPB, BANK1, MIC1, CA195, CO3, CO9, CAH1, CAH2, CALR, CAPG, CD24, CD63, CDD, CEAM3, CEAM5, CEAM6 CGHB, CH3L1, KCRB, CLC4D, CLUS, CNN1, COR1C, CRP, CSF1, CTNB1, CATD, CATS, CATZ, CUL1, SYDC, DEF1, DEF3, DESM, DPP4, DPYL2, DYHC1, ECH1, EF2, IF4A3, ENOA EZR1, NIBL2, SEPR, FBX4, FIBB, FIBG, FHL1, FLNA, FRMD3, FRIH, FRIL, FUCO, GBRA1, G3P, SYG, GDF15, GELS, GSTP1, HABP2, HGF, 1A68, HMGB1, ROA1, ROA2, HNRPF, HPT, HS90B, ENPL, GRP75, HSPB1, CH60, SIAL, IFT74, IGF1, IGHA2, IL2RB, IL8, IL9, RASK, K1C19, K2C8, LAMA2, LEG3, LMNB1, MARE1, MCM4, MIF, MMP7, MMP9, CD20, MYL6, MYL9, NDKA, NNMT, A1AG1, PCKGM, PDIA3, PDIA6, PDXK, PEBP1, PIPNA, KPYM, UROK, IPYR, PRDX1, KPCD1, PRL, TMG4, PSME3, PTEN, FAK1, FAK2, RBX1, REG4, RHOA, RHOB, RHOC, RSSA, RRBP1, S10AB, S10AC, 510A8, 5109, SAA1, SAA2, SEGN, SDCG3, DHSA, SBP1, SELPL, SEP9, A1AT, AACT, ILEU, SPB6, SF3B3, SKP1, ADT2, ISK1, SPON2, OSTP, SRC, STK11, HNRPQ, TAL1, TRFE, TSP1, TIMP1, TKT, TSG6, TR10B, TNF6B, P53, TPM2, TCTP, TRAP1, THTR, TBB1, UGDH, UGPA, VEGFA, VILI, VIME, VNN1, 1433Z, CCR5, FUCO, and combinations thereof in a biological sample from the subject.

### Claim 137 (depends on 136)

The method of claim 136, wherein the one or more peptides is selected from the group consisting of SPB6, FRIL, P53, 1A68, ENOA, TKT.

### Claim 138 (depends on 136)

The method of claim 136, wherein the one or more peptides is selected from the group consisting of SPB6, FRIL, P53, 1A68, ENOA, TKT, TSG6, TPM2, ADT2, FHL1, CCR5, CEAM5, SPON2, 1A68, RBX1, COR1C, VIME, PSME3, and combinations thereof in a biological sample from the subject.

### Claim 139 (depends on 136)

The method of claim 136, wherein the one or more peptides is selected from the group consisting of SPB6, FRIL, P53, 1A68, ENOA, TKT, TSG6, TPM2, ADT2, FHL1, CCR5, CEAM5, SPON2, 1A68, RBX1, COR1C, VIME, PSME3, MIC1, STK11, IPYR, SBP1, PEBP1, CATD, HPT, ANXA5, ALDOA, LAMA2, CATZ, ACTB, AACT, and combinations thereof in a biological sample from the subject.
